MediWound (NASDAQ:MDWD) Stock Lifted to Sell by Wall Street Zen

Wall Street Zen upgraded shares of MediWound (NASDAQ:MDWD) from a strong sell rating to a sell rating in a research note published on Saturday,Wall Street Zen reports.

MDWD has been the subject of several other reports. Alliance Global Partners reaffirmed a “buy” rating on shares of MediWound in a report on Wednesday, September 16th. Oppenheimer reissued an “outperform” rating and issued a $30.00 target price (down from $32.00) on shares of MediWound in a report on Friday, August 14th. TD Cowen reissued a “buy” rating on shares of MediWound in a report on Thursday. Finally, Weiss Ratings cut MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $33.00.

MediWound Trading Up 0.1%

Shares of MediWound stock opened at $13.84 on Friday. MediWound has a 12-month low of $12.52 and a 12-month high of $20.03. The stock has a market cap of $177.84 million, a PE ratio of -7.69 and a beta of 0.14. The company has a 50-day moving average of $13.66 and a two-hundred day moving average of $15.07.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). The company had revenue of $3.09 million for the quarter, compared to analyst estimates of $2.59 million. MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. On average, sell-side analysts forecast that MediWound will post -2.37 EPS for the current fiscal year.

Insider Buying and Selling at MediWound

In related news, COO Shmuel Hess sold 3,958 shares of MediWound stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $12.92, for a total transaction of $51,137.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 9.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On MediWound

An institutional investor recently raised its position in MediWound stock. Silverberg Bernstein Capital Management LLC raised its stake in MediWound Ltd. (NASDAQ:MDWD) by 8.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 200,005 shares of the biopharmaceutical company’s stock after acquiring an additional 16,081 shares during the quarter. MediWound makes up 1.8% of Silverberg Bernstein Capital Management LLC’s portfolio, making the stock its 16th biggest holding. Silverberg Bernstein Capital Management LLC owned approximately 1.56% of MediWound worth $3,222,000 as of its most recent filing with the Securities & Exchange Commission. 46.83% of the stock is owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative enzymatic therapies for tissue injury and wound care. The company’s products are designed to remove damaged or nonviable tissue while helping preserve healthy tissue, supporting wound management and healing.

MediWound’s lead commercial product is NexoBrid, a topical bromelain-based therapy used for the enzymatic removal of eschar in adults with deep partial-thickness and full-thickness thermal burns.